Marsha Schlenter1, Vanessa Berneking1,2, Barabara Krenkel1, Felix M Mottaghy3, Thomas-Alexander Vögeli4, Michael J Eble1, Michael Pinkawa5,6. 1. Department of Radiation Oncology, RWTH Aachen University, Pauwelsstr. 30, 52072, Aachen, Germany. 2. Department of Radiation Oncology, MediClin Robert Janker Klinik, Villenstr. 8, 53129, Bonn, Germany. 3. Department of Nuclear Medicine, RWTH Aachen University, Pauwelsstr. 30, 52072, Aachen, Germany. 4. Department of Urology, RWTH Aachen University, Pauwelsstr. 30, 52072, Aachen, Germany. 5. Department of Radiation Oncology, RWTH Aachen University, Pauwelsstr. 30, 52072, Aachen, Germany. michael.pinkawa@post.rwth-aachen.de. 6. Department of Radiation Oncology, MediClin Robert Janker Klinik, Villenstr. 8, 53129, Bonn, Germany. michael.pinkawa@post.rwth-aachen.de.
Abstract
PURPOSE: To analyze clinical results and quality of life of patients with localized prostate cancer after irradiation of the prostate with an 18F-choline-PET/CT-based simultaneous integrated boost (SIB) in comparison to a control group without SIB. METHODS: A total of 134 patients underwent intensity-modulated radiotherapy from 2007-2010. All patients received a total dose of 76 Gy with 2 Gy fractions to the prostate; 67 patients received an additional SIB of 80 Gy. The median follow-up was 65 months. Quality of life was evaluated with the EPIC (Expanded Prostate Cancer Index Composite) questionnaire. RESULTS: Baseline characteristics were similar in both groups (prostate-specific antigen 11 ng/ml vs. 8 ng/ml, p = 0.20, Gleason score <6 in 36% vs. 46%, p = 0.22, with vs. without SIB). No prostate cancer-related death was observed. No significant difference of quality of life scores was found. The largest difference after 5-6 years in comparison to baseline was reported for sexual bother (mean 15 vs. 17 points with vs. without SIB). Mean urinary scores did not decrease. Bowel bother scores changes were larger in the SIB group (mean 5 vs. 2 points, dependent on SIB volume), with increased bowel problems (15 vs. 2% big/moderate problem with bowel movements, p = 0.03). However, a trend towards higher efficacy with SIB resulted (biochemical recurrence-free survival of 92% vs. 85%, p = 0.17). CONCLUSIONS: The first long-term analysis of patients treated with SIB based on molecular imaging with 18-F-choline-PET/CT showed an excellent biochemical recurrence-free survival, but a larger percentage of bowel problems in comparison to the control group.
PURPOSE: To analyze clinical results and quality of life of patients with localized prostate cancer after irradiation of the prostate with an 18F-choline-PET/CT-based simultaneous integrated boost (SIB) in comparison to a control group without SIB. METHODS: A total of 134 patients underwent intensity-modulated radiotherapy from 2007-2010. All patients received a total dose of 76 Gy with 2 Gy fractions to the prostate; 67 patients received an additional SIB of 80 Gy. The median follow-up was 65 months. Quality of life was evaluated with the EPIC (Expanded Prostate Cancer Index Composite) questionnaire. RESULTS: Baseline characteristics were similar in both groups (prostate-specific antigen 11 ng/ml vs. 8 ng/ml, p = 0.20, Gleason score <6 in 36% vs. 46%, p = 0.22, with vs. without SIB). No prostate cancer-related death was observed. No significant difference of quality of life scores was found. The largest difference after 5-6 years in comparison to baseline was reported for sexual bother (mean 15 vs. 17 points with vs. without SIB). Mean urinary scores did not decrease. Bowel bother scores changes were larger in the SIB group (mean 5 vs. 2 points, dependent on SIB volume), with increased bowel problems (15 vs. 2% big/moderate problem with bowel movements, p = 0.03). However, a trend towards higher efficacy with SIB resulted (biochemical recurrence-free survival of 92% vs. 85%, p = 0.17). CONCLUSIONS: The first long-term analysis of patients treated with SIB based on molecular imaging with 18-F-choline-PET/CT showed an excellent biochemical recurrence-free survival, but a larger percentage of bowel problems in comparison to the control group.
Entities:
Keywords:
18F-choline-PET/CT; Image-guided radiotherapy; Intensity-modulated radiotherapy; Prostate cancer; Quality of life
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Stefan Höcht; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Tobias Hölscher; Thomas Martin; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel Journal: Strahlenther Onkol Date: 2016-09-14 Impact factor: 3.621
Authors: Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu Journal: Eur J Nucl Med Mol Imaging Date: 2015-11-23 Impact factor: 9.236
Authors: Michael Pinkawa; Martin Pursch-Lee; Branka Asadpour; Bernd Gagel; Marc D Piroth; Jens Klotz; Sandra Nussen; Michael J Eble Journal: Strahlenther Onkol Date: 2008-12-24 Impact factor: 3.621
Authors: Axel Wetter; Felix Nensa; Marcus Schenck; Philipp Heusch; Thorsten Pöppel; Andreas Bockisch; Michael Forsting; Thomas W Schlosser; Thomas C Lauenstein; James Nagarajah Journal: PLoS One Date: 2014-07-17 Impact factor: 3.240
Authors: Nina-Sophie Schmidt-Hegemann; Chukwuka Eze; Minglun Li; Paul Rogowski; Christian Schaefer; Christian Stief; Alexander Buchner; Constantinos Zamboglou; Wolfgang Peter Fendler; Ute Ganswindt; Clemens Cyran; Peter Bartenstein; Claus Belka; Harun Ilhan Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Hans Theodor Eich; Kambiz Rahbar; Sergiu Scobioala; Christopher Kittel; Heidi Wolters; Sebastian Huss; Khaled Elsayad; Robert Seifert; Lars Stegger; Matthias Weckesser; Uwe Haverkamp Journal: Ann Nucl Med Date: 2021-03-19 Impact factor: 2.668
Authors: Pierpaolo Alongi; Riccardo Laudicella; Helena Lanzafame; Andrea Farolfi; Paola Mapelli; Maria Picchio; Irene A Burger; Andrei Iagaru; Fabio Minutoli; Laura Evangelista Journal: Cancers (Basel) Date: 2022-03-31 Impact factor: 6.639
Authors: Stratos Vassis; Beatrice Nöldeke; Hans Christiansen; Christoph A von Klot; Roland Merten Journal: Strahlenther Onkol Date: 2020-02-10 Impact factor: 3.621